April 13, 2016
(New York Times) – The editors of The Journal of the American Medical Association make a good case for broadly sharing such clinical trial data. While many large pharmaceutical companies make data from clinical drug trials available to outside researchers, many academic institutions and smaller companies don’t. And even when the data is made available, analysis by outside researchers remains relatively uncommon. A recent study found that on three data-sharing platforms, researchers had requested access to the data from just 15.5 percent of the trials available.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.